论文部分内容阅读
目的探讨瑞格列奈联合自拟太子参降糖方治疗2型糖尿病(非肥胖型,NIDDM)患者的疗效与临床意义。方法选择本社区新确诊或服用瑞格列奈的NIDDM患者112例,按档案号奇偶数分为AB两组,A组54例:服用低剂量瑞格列奈治疗;B组58例:服用低剂量瑞格列奈联合太子参降糖方治疗。两组患者血糖控制不佳时从低剂量开始加用二甲双胍片。研究前检查患者临床症状、体质指数(BMI)、血压(SBP/DBP);检测空腹血糖(FPG)、非空腹血糖(NFPG)、糖化血红蛋白(Hb A1C)、胰岛素抵抗指数(HOMA-IR)、总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、尿白蛋白/肌酐比值(ACR)、尿白蛋白排泄率(MALB);记录合并疾病的相关情况。分别在治疗12周和24周后复查上述各项指标并进行统计学分析。结果治疗12周后,B组FPG、Hb A1C、HOMA-IR、LDL-C、MALB、ACR均较A组低,24周后降低明显,差异有统计学意义(P<0.05);B组的BMI及HDL-C较A组高,差异有统计学意义(P<0.05);其他项目两组比较,差异无统计学意义(P>0.05)。结论瑞格列奈联合太子参降糖方治疗NIDDM,比单用瑞格列奈效果好,可有效改善糖尿病患者的临床症状和相关指标。
Objective To investigate the curative effect and clinical significance of repaglinide in combination with self-made Taizi ginseng hypoglycemic prescription in the treatment of type 2 diabetes (non-obese, NIDDM) patients. Methods One hundred and twelve newly diagnosed or treated patients with nidrol in repaglinide were divided into two groups according to the number of odd and even files, 54 in group A: low-dose repaglinide; 58 in group B: Dose of repaglinide combined with heterophyllan hypoglycemic treatment. Two groups of patients with poor blood glucose control from low doses began to add metformin tablets. The clinical symptoms, body mass index (BMI) and blood pressure (SBP / DBP) were examined before the study. The levels of fasting blood glucose (FPG), non-fasting blood glucose (NFPG), HbA1c, HOMA-IR, Total cholesterol TC, TG, HDL-C, LDL-C, ACR and MALB ); Record the associated conditions of the merger. Respectively after 12 weeks and 24 weeks of treatment, the above indexes were reviewed and statistically analyzed. Results After 12 weeks of treatment, the levels of FPG, Hb A1C, HOMA-IR, LDL-C, MALB and ACR in group B were lower than those in group A and decreased significantly after 24 weeks (P <0.05) BMI and HDL-C were significantly higher than those in group A (P <0.05). There was no significant difference in other items between the two groups (P> 0.05). Conclusion Repaglinide combined with heterophyllan hypoglycemic treatment of NIDDM, compared with the single effect of repaglinide, which can effectively improve the clinical symptoms and related indicators of diabetic patients.